Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling

ConditionsSchizophrenia Schizophrenia and Related Disorders Bipolar Disorder Bipolar and Related Disorders Major Depressive Disorder Major Depression Severe Ketogenic Dieting Ketosis Metabolic Disease Metabolic Syndrome

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-80

SponsorStanford University

About this trial

The goal of this randomized clinical trial is to be adequately powered to evaluate the effect of ketogenic metabolic therapy on the quality of life in serious mental illness, schizophrenia, bipolar disorder, major depressive disorder.

Eligibility criteria

Qualifiers

diagnosed with bipolar disorder (BD), major depressive disorder (MDD), and or schizophrenia

Meet DSM V criteria for BD (any subtype)

Not mild

>40 on BPRS

Disqualifiers

has started the ketogenic diet or was in ketosis within 3 months of wanting to enroll

pregnant or nursing

insulin dependent

comorbidity of developmental delay

Trial design

Treatments tested in this trial

LCHF Ketogenic Diet
Diet-as-Usual (DAU)

Treatment groups

120 Participants

are divided into 2 treatment groups

Locations

Stanford University94304, Palo AltoCalifornia, United States

Sponsors and collaborators

Stanford University

Lead sponsor

Source ClinicalTrials.gov